Although there were previously concerns regarding long-term inhibition of VEGF, leading to inhibited neuro-protective effect, anti-VEGF agent is recently viewed as a safe management for neovascularization and macular edema secondary to RP.[5] Occasionally, CNV may be successfully managed with a single intravitreal anti-VEGF injection, but most cases require more than a one-year period to achieve stabilization in RP-related CNV.[6] In our case, anti-VEGF agents were also effective in exudative RD and macular edema, but there might be recurrence in the following months. The gene discussed is VEGFA; the disease is retinitis pigmentosa 1.